Phase III Study: Rituxan Improved PFS By 79% In Advanced Follicular Lymphoma
ASCO Calls On NCI To Double Funding For Cooperative Group Clinical Trials
Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase
Bosutinib Vs. Imatinib Study Didn’t Meet Primary Endpoint
Autologous BMT Equivalent To Allogeneic For Myeloma
Non-Adherence To Protocol Explains Outcome Differences In Hispanic Children With ALL
Afinitor Delayed Progression Compared To Tamoxifen Alone In Randomized Phase II Study
AZURE Trial: Zoledronic Acid Didn’t Improve DFS In Stage II/III
Survival For ALL Increased To 94 Percent In Recent Years
TTF Increased Survival Compared To Chemotherapy
Randomized Trial Finds Sunscreen Use Cuts Risk Of Developing Melanoma
Clinical Trials Approved By NCI CTEP Last Month
Trending Stories
- Solving problems doctors can’t fix: How Georgetown’s medical-legal partnership saves lives by including lawyers on cancer care teams
Why every cancer center needs a Cancer LAW Project - Before the Olympics were smoke-free, tobacco brand deals ran rampant
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ACS is using an AI-powered platform in the largest-ever population study of Black women
Time and resources freed up from data management will go to outreach and access - Georgetown-MedStar: Patients with cancer can rely on our lawyers to fight legal issues that harm health
- Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC